| 1 |
NCT02948478 |
Recruiting |
Economic and Social Disparities and Breast Cancer |
|
- Other: Exposed
- Other: Non exposed
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
- National Cancer Institute, France
- Paris West University Nanterre La Défense
- (and 2 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
1040 |
Female |
18 Years and older (Adult, Senior) |
NCT02948478 |
K160202
ID RCB 2016-A00589-42 |
DESSEIN |
December 2016 |
October 2018 |
October 2019 |
October 28, 2016 |
January 16, 2017 |
|
- Hôpital Jean Verdier
Bondy, France - Centre Hospitalier Intercommunal Créteil
Creteil, France - Hôpital Henri Mondor
Créteil, France - (and 12 more...)
|
| 2 |
NCT02945579 |
Recruiting |
Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy |
|
- Procedure: Breast Biopsy
- Radiation: Radiation Therapy
- Behavioral: Questionnaire
|
Interventional |
Not Applicable |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of Treatment Regimen
- Ipsilateral Breast Tumor Recurrence-Free Survival (IBT-RFS)
|
50 |
Female |
40 Years and older (Adult, Senior) |
NCT02945579 |
2016-0046
NCI-2016-01929 |
|
January 20, 2017 |
January 2022 |
January 2022 |
October 26, 2016 |
December 29, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States - MD Anderson at Cooper
Voorhees, New Jersey, United States - Levine Cancer Institute, Carolinas Medical Center
Charlotte, North Carolina, United States - (and 2 more...)
|
| 3 |
NCT02823262 |
Recruiting |
A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older |
- Breast Cancer
- Estrogen Receptor Positive Breast Cancer
- Node-negative Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
|
- Other: Breast Cancer Treatment Decision Aid for women 70+
- Other: Usual Care
|
Interventional |
Not Applicable |
- Dana-Farber Cancer Institute
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change in Decisional Conflict Scale at 1 week
- Knowledge score using our knowledge test
- Change in Stage of Decision-Making at one week using one-item tool
- (and 13 more...)
|
312 |
Female |
70 Years and older (Senior) |
NCT02823262 |
16-117 |
|
July 2016 |
July 2022 |
July 2024 |
July 6, 2016 |
February 1, 2018 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
| 4 |
NCT02753686 |
Recruiting |
Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy |
- HR+ HER2- Postmenopausal Advanced Breast Cancer
|
- Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
- Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
|
Observational |
|
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Duration on Treatment
- Number of participants with adverse events in ET and ET+TT cohorts
- Time to Treatment Failure (TTF)
- (and 6 more...)
|
320 |
Female |
18 Years and older (Adult, Senior) |
NCT02753686 |
CRAD001YCA09 |
Treat ER+ight |
March 15, 2016 |
December 2, 2019 |
December 2, 2019 |
April 28, 2016 |
February 7, 2018 |
|
- Novartis Investigative Site
Burnaby, British Columbia, Canada - Novartis Investigative Site
Richmond, British Columbia, Canada - Novartis Investigative Site
Vancouver, British Columbia, Canada - (and 14 more...)
|
| 5 |
NCT03240224 |
Recruiting |
Bioinformation Therapy for Breast Cancer |
|
- Device: Cancer ablation
- Drug: Life information rehabilitation therapy
|
Interventional |
Phase 2
Phase 3 |
- Fuda Cancer Hospital, Guangzhou
- Shengxin Biotechnology Institute, Beijing
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relief degree of tumors
- Progress free survival（PFS）
- Overall survival（OS）
|
120 |
All |
20 Years to 80 Years (Adult, Senior) |
NCT03240224 |
Bioinformation-breast |
|
September 2, 2017 |
September 2, 2018 |
September 2, 2020 |
August 7, 2017 |
August 7, 2017 |
|
- Fuda cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China
|
| 6 |
NCT03127332 |
Not yet recruiting |
Metastatic Breast Cancer Treatment Planning |
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Adherence (by providers) to evidence-based treatment recommendations for patients with metastatic breast cancer.
- Number of patients who are fit, intermediate fit, or frail as assessed by a modified geriatric assessment and a description of the chemotherapy regimens they are prescribed
- ER utilization and hospitalization in elderly patients with metastatic breast cancer
|
100 |
Female |
18 Years and older (Adult, Senior) |
NCT03127332 |
G413 |
|
July 1, 2018 |
December 30, 2018 |
December 31, 2018 |
April 25, 2017 |
January 25, 2018 |
|
|
| 7 |
NCT02112682 |
Recruiting |
Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy |
|
- Procedure: Completion axillary treatment
|
Interventional |
Not Applicable |
- Maastricht University Medical Center
- Borstkanker Onderzoek Groep
- Dutch Cancer Society
- Maastricht University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
878 |
Female |
18 Years and older (Adult, Senior) |
NCT02112682 |
BOOG 2013-07
KWF UM 2013-5920 |
|
June 2014 |
June 2027 |
June 2027 |
April 14, 2014 |
April 21, 2017 |
|
- Maastricht University Medical Centre+
Maastricht, Limburg, Netherlands - Flevoziekenhuis
Almere, Netherlands - Meander Medisch Centrum
Amersfoort, Netherlands - (and 28 more...)
|
| 8 |
NCT02701907 |
Recruiting |
EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies |
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Other
|
- The primary endpoint is the rate of patients with tumors harboring a low level of genomic alteration (mutation, amplification or deletion) in genes (i.e. mutation, amplification, deletion) identified as causally implicated in cancer
- The secondary endpoint is the rate of tumors with low level of genomic alterations between the EXPRESS cohort and control cohorts of patients.
- Exploratory analyses will be performed to compare the profiles between the EXPRESS and the control cohorts of patients, to identify novel candidate somatic molecular profiles
|
264 |
All |
18 Years and older (Adult, Senior) |
NCT02701907 |
UC-0105/1508 |
EXPRESS |
February 2016 |
February 2019 |
August 2019 |
March 8, 2016 |
February 10, 2017 |
|
- Dr Laetitia STEFANI
Annecy, France
|
| 9 |
NCT03151447 |
Recruiting |
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer |
|
- Radiation: stereotactic body radiation therapy
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
|
18 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT03151447 |
FDRT-BC005 |
|
March 6, 2017 |
March 2018 |
March 2018 |
May 12, 2017 |
May 12, 2017 |
|
- Fudan University Shanghai Cancer Center
Shanghai, China
|
| 10 |
NCT02700386 |
Recruiting |
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes |
|
- Combination Product: Adjuvant Hypofractionated Radiation
|
Interventional |
Phase 2 |
- University of Colorado, Denver
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03
- Number of participants with lymphedema severity by measuring interlimb circumference
- Number of participants with symptomatic rib fracture as measured by plain film or CT
- (and 6 more...)
|
112 |
Female |
18 Years to 101 Years (Adult, Senior) |
NCT02700386 |
15-1329.cc |
|
August 11, 2016 |
August 2020 |
August 2020 |
March 7, 2016 |
March 23, 2018 |
|
- University of Colorado Hospital
Aurora, Colorado, United States - Memorial Hospital
Colorado Springs, Colorado, United States - Poudre Valley Hospital
Fort Collins, Colorado, United States
|
| 11 |
NCT02308085 |
Recruiting |
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer |
|
- Other: Endocrine therapy interruption
|
Interventional |
Not Applicable |
- International Breast Cancer Study Group
- Alliance for Clinical Trials in Oncology
- NCIC Clinical Trials Group
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Breast Cancer free interval (BCFI)
- Information on Menstruation recovery and pattern
- Pregnancy rate (determined by pregnancy test)
- (and 5 more...)
|
500 |
Female |
18 Years to 42 Years (Adult) |
NCT02308085 |
IBCSG 48-14 / BIG 8-13
Alliance A221405
NCIC CTG MAC.18 |
POSITIVE |
December 2014 |
June 2020 |
December 2028 |
December 4, 2014 |
December 13, 2017 |
|
- Cedars Sinai Medical Centre
Los Angeles, California, United States - Stanford Cancer Institute
Palo Alto, California, United States - University of Colorado Cancer Centre - Anschutz Cancer Pavilion
Aurora, Colorado, United States - (and 165 more...)
|
| 12 |
NCT02890316 |
Recruiting |
Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment |
|
- Other: Homeopathy remedy
- Radiation: Radiation as adjuvant therapy for breast cancer
|
Interventional |
Phase 1
Phase 2 |
- Sheba Medical Center
- Technion, Israel Institute of Technology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Physiological monitoring of changes in anxiety during radiotherapy with and without homeopathy treatment.
- Physiological monitoring of changes in attention during radiotherapy with and without homeopathy treatment.
|
64 |
Female |
18 Years to 90 Years (Adult, Senior) |
NCT02890316 |
2370-15 |
|
July 2016 |
July 2017 |
|
September 7, 2016 |
September 7, 2016 |
|
- Merav Ben David
Ramat-Gan, Israel
|
| 13 |
NCT03204734 |
Recruiting |
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer |
|
- Drug: Capecitabine
- Drug: endocrine therapy
|
Interventional |
Phase 2 |
- Zhejiang Cancer Hospital
- Zhejiang Cancer Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival(PFS)
- clinical benefit rate(CBR)
- overall survival
- (and 3 more...)
|
132 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03204734 |
ZJCH15009 |
|
January 1, 2016 |
December 30, 2020 |
December 30, 2021 |
July 2, 2017 |
July 2, 2017 |
|
- Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
|
| 14 |
NCT02750358 |
Recruiting |
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer |
- Breast Cancer
- Early Stage
- Triple Negative Breast Cancer
|
- Drug: Enzalutamide
- Behavioral: assessment
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Medivation, Inc.
- Astellas Pharma Inc
- Memorial Sloan Kettering Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The treatment discontinuation rate of enzalutamide in the adherent population
|
200 |
Female |
18 Years and older (Adult, Senior) |
NCT02750358 |
15-307 |
|
May 19, 2016 |
May 2019 |
May 2019 |
April 25, 2016 |
November 17, 2017 |
|
- Hartford Healthcare Cancer Institute @ Hartford Hospital
Hartford, Connecticut, United States - Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - (and 9 more...)
|
| 15 |
NCT02401685 |
Recruiting |
POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer |
|
- Other: Adjuvant therapy
- Procedure: Axillary treatment
|
Interventional |
Not Applicable |
- Derby Hospitals NHS Foundation Trust
- University of Nottingham
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Axillary recurrence
- Arm morbidity
- Quality of life
- (and 11 more...)
|
1900 |
Female |
18 Years and older (Adult, Senior) |
NCT02401685 |
RD-5103-001-13
ISRCTN Number |
POSNOC |
January 2014 |
March 2023 |
December 2023 |
March 30, 2015 |
January 31, 2018 |
|
- Royal Adelaide Hospital
Adelaide, Australia - Bankstown-Lidcocombe Hospital
Bankstown, Australia - Maeter Hospital
Brisbane, Australia - (and 47 more...)
|
| 16 |
NCT02266602 |
Recruiting |
Intraoperative Radiation Therapy in Early Stage Breast Cancer |
|
- Radiation: Intraoperative Radiation Therapy
|
Interventional |
Not Applicable |
- Benaroya Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Local Disease Relapse
- Disease specific and overall survival
|
500 |
Female |
45 Years and older (Adult, Senior) |
NCT02266602 |
11143 |
IORTBreast |
February 2012 |
February 2019 |
February 2022 |
October 17, 2014 |
July 17, 2017 |
|
- Virginia Mason Medical Center
Seattle, Washington, United States
|
| 17 |
NCT02889874 |
Recruiting |
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer |
- Early Stage Breast Carcinoma
|
- Radiation: Omission of radiation therapy
|
Interventional |
Not Applicable |
- Breast Cancer Trials, Australia and New Zealand
- Breast International Group
- International Breast Cancer Study Group
- Breast Cancer Trials, Australia and New Zealand
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Local recurrence rate after breast conserving surgery
- Local-regional recurrence-free interval (LRRFI)
- Distant recurrence-free interval (DRFI)
- (and 8 more...)
|
1167 |
Female |
50 Years and older (Adult, Senior) |
NCT02889874 |
ANZ1601/BIG 16-02
2016-003527-33 |
EXPERT |
August 21, 2017 |
December 2023 |
December 2023 |
September 7, 2016 |
April 19, 2018 |
|
- The Canberra Hospital
Canberra, Australian Capital Territory, Australia - Macarthur Cancer Therapy Centre
Campbelltown, New South Wales, Australia - St Vincent's Hospital, Sydney
Darlinghurst, New South Wales, Australia - (and 26 more...)
|
| 18 |
NCT02701244 |
Recruiting |
A Registry Study of Breast Microseed Treatment |
|
- Radiation: Permanent Breast Seed Implant (PBSI)
|
Observational |
|
- Concure Oncology-Breast Microseed Inc.
- Concure Oncology-Breast Microseed Inc.
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Serious Adverse Events (SAE)
- Breast Cancer Recurrence
- Permanent Breast Seed Implant (PBSI) Side Effects
- (and 2 more...)
|
420 |
Female |
50 Years and older (Adult, Senior) |
NCT02701244 |
BMS-001 |
|
July 2016 |
July 2021 |
July 2026 |
March 8, 2016 |
March 19, 2018 |
|
- Allegheny General Hospital
Pittsburgh, Pennsylvania, United States - Mary Washington Hospital
Fredericksburg, Virginia, United States - Swedish Cancer Institute
Seattle, Washington, United States
|
| 19 |
NCT03213925 |
Recruiting |
Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer |
- Breast Cancer
- Radiation Therapy
|
- Radiation: Radiation therapy
|
Interventional |
Phase 2 |
- Instituto do Cancer do Estado de São Paulo
- Instituto do Cancer do Estado de São Paulo
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ipsilateral breast tumor recurrence (IBTR)
|
1 |
Female |
40 Years to 75 Years (Adult, Senior) |
NCT03213925 |
RT alone |
|
June 1, 2017 |
July 1, 2020 |
July 1, 2025 |
July 11, 2017 |
July 11, 2017 |
|
- Department of Radiology and Oncology of University of São Paulo - Radiation Oncology Unit, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
|
| 20 |
NCT02764541 |
Recruiting |
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) |
|
- Drug: Letrozole
- Drug: Tamoxifen
- Drug: Palbociclib
- Drug: Endocrine Therapy
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Pfizer
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Window Phase:To evaluate the difference in anti-proliferative activity of letrozole versus tamoxifen within cohorts of hormone receptor positive breast cancer for patients with invasive lobular and ductal carcinoma.
- Treatment Phase: To evaluate the pathologic complete response (pCR) of endocrine therapy plus palbociclib and of endocrine therapy alone in breast cancer patients diagnosed with hormone receptor positive invasive breast cancer
- Overrall Response Rate
- (and 2 more...)
|
180 |
Female |
18 Years and older (Adult, Senior) |
NCT02764541 |
16-052 |
|
May 2016 |
November 2019 |
November 2019 |
May 6, 2016 |
February 1, 2018 |
|
- Stamford Hospital
Stamford, Connecticut, United States - Eastern Maine Medical Center
Brewer, Maine, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - (and 3 more...)
|
| 21 |
NCT02965755 |
Recruiting |
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins |
|
- Other: Treatment recommendation
|
Interventional |
Not Applicable |
- Sidney Kimmel Comprehensive Cancer Center
- Foundation Medicine
- Sidney Kimmel Comprehensive Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess next generation sequencing of plasma tumor DNA (ptDNA) to identify genetic alterations present in tumor tissue
- To assess plasma tumor DNA (ptDNA) levels over time
- To determine if levels in ptDNA correspond with levels of tumor markers
|
200 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02965755 |
J16146
IRB00117742 |
IMAGE-II |
January 26, 2018 |
July 2020 |
July 2022 |
November 17, 2016 |
February 2, 2018 |
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
| 22 |
NCT02624973 |
Recruiting |
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial |
|
- Drug: Neoadjuvant tamoxifen + goserelin (premenopausal women)
- Drug: Neoadjuvant letrozole (postmenopausal women)
- Drug: Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
- (and 13 more...)
|
Interventional |
Phase 2 |
- Haukeland University Hospital
- Helse Vest
- Pfizer
- AstraZeneca
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Predictive and prognostic value of mutations in 300 cancer-related genes assessed in breast cancer tissue by next generation sequencing before starting neoadjuvant therapy.
- To assess genetic/epigenetic changes within the tumor tissue during therapy
- The objective response rate (ORR) of personalized medicine, compared to ORR for best standard-of-care using historical data for comparison
- (and 5 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02624973 |
2015/8463 |
PETREMAC |
April 2016 |
June 2020 |
June 2030 |
December 9, 2015 |
November 6, 2017 |
|
- Akershus University Hospital
Lørenskog, Akershus, Norway - Haukeland University Hospital
Bergen, Hordaland, Norway - Helse Fonna
Haugesund, Rogaland, Norway - (and 4 more...)
|
| 23 |
NCT02898727 |
Recruiting |
A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer |
|
|
Interventional |
Phase 2 |
- Trans-Tasman Radiation Oncology Group (TROG)
- Trans-Tasman Radiation Oncology Group (TROG)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- to assess the percentage of patients treated with whole brain radiotherapy within 12 months after completion of local therapy
- To describe distant brain failure incidence (overall and by number of treated metastases)
- To describe local brain failure incidence, at any site of SRS or surgery
- (and 5 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02898727 |
TROG 16.02 |
Local HER-O |
November 20, 2017 |
May 2020 |
May 2020 |
September 13, 2016 |
February 28, 2018 |
|
- Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
|
| 24 |
NCT02581670 |
Recruiting |
Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer |
- Breast Cancer
- Metastasis to Liver
- Metastasis to Lung
|
- Radiation: stereotactic radiation therapy (SRT)
|
Interventional |
Phase 2 |
- Istituto Clinico Humanitas
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity in oligometastatic breast cancer patients monitoring using CTCAE v.4
- Local control of disease after SBRT according to EORTC questionnaire
- Progression free survival using Kaplan-Meyer statistical curves
- (and 2 more...)
|
40 |
Female |
18 Years and older (Adult, Senior) |
NCT02581670 |
1437 |
|
July 2015 |
July 2018 |
July 2020 |
October 21, 2015 |
October 21, 2015 |
|
- Istituto Clinico Humanitas
Rozzano, Milano, Italy
|
| 25 |
NCT03285412 |
Recruiting |
CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer |
|
- Drug: Ribociclib
- Other: Endocrine therapy
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- Novartis
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants That Complete 12 Months of Treatment
- Comparison of Adverse Events Among Participants Treated With Endocrine therapy for ≤ 5 Years to Participants Treated With Endocrine Therapy for > 5 Years
- Number of participants who have a switch in endocrine therapy
- Disease-free survival (DFS)
|
120 |
Female |
18 Years and older (Adult, Senior) |
NCT03285412 |
17-232 |
LEADER |
December 12, 2017 |
February 28, 2021 |
February 28, 2025 |
September 18, 2017 |
March 16, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
| 26 |
NCT02999477 |
Recruiting |
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer |
|
- Drug: Pembrolizumab
- Drug: Nab-Paclitaxel
- Procedure: Biopsy
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Merck Sharp & Dohme Corp.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in PD-L1 Expression By Immunohistochemistry From Baseline Biopsy to Biopsy After 2-Week Treatment (biopsy 2)
- The Absolute Change in PD-L1 Expression By Immunohistochemistry From Baseline Biopsy to Biopsy After Treatment with Nab-Paclitaxel or Pembrolizumab Monotherapy (biopsy 3)
- The Absolute Change in Expression of Core Immune Biomarkers (stromal TILs; PD-1; PD-L2; CD8) from Baseline Biopsy to Biopsy After 2-Week Treatment (biopsy 2)
- (and 5 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02999477 |
16-466 |
|
February 23, 2017 |
January 2020 |
January 2023 |
December 21, 2016 |
October 20, 2017 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 27 |
NCT01993498 |
Recruiting |
Breast Cancer Toxicity |
- Breast Cancer Nos Metastatic Recurrent
|
- Procedure: blood sampling
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Evaluation of chronic toxicity in patients treated for non-metastatic breast cancer
|
20000 |
Female |
18 Years and older (Adult, Senior) |
NCT01993498 |
UC 0140/1103 CANTO
2011-A01095-36 |
CANTO |
February 2012 |
March 2022 |
March 2026 |
November 25, 2013 |
May 28, 2015 |
|
- Gustave roussy
Villejuif, France
|
| 28 |
NCT02668666 |
Recruiting |
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer |
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Estrogen Receptor Positive Breast Cancer
- (and 2 more...)
|
- Drug: Palbociclib
- Drug: Tamoxifen
|
Interventional |
Phase 2 |
- Oana Danciu, MD
- Pfizer
- Big Ten Cancer Research Consortium
- Big Ten Cancer Research Consortium
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rates in Subjects with HR(+)/HER2(-) Advanced Breast Cancer who have not Received Prior Systemic Anti-Cancer Therapies for their Advanced/Metastatic Disease Treated with Palbociclib in Combination with Tamoxifen
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Progression-Free Survival (PFS) in Subjects with HR(+)/HER2(-) Advanced Breast Cancer who have not Received Prior Systemic Anti-Cancer Therapies for their Advanced/Metastatic Disease Treated with Palbociclib in Combination with Tamoxifen
- (and 2 more...)
|
71 |
All |
18 Years and older (Adult, Senior) |
NCT02668666 |
BTCRC BRE15-016 |
|
June 2016 |
June 2018 |
June 2019 |
January 29, 2016 |
January 26, 2018 |
|
- University of Illinois Cancer Center
Chicago, Illinois, United States - Michigan State University
Lansing, Michigan, United States - University of Minnesota
Minneapolis, Minnesota, United States - (and 4 more...)
|
| 29 |
NCT00496288 |
Recruiting |
Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer |
|
- Radiation: Prophylactic radiation to the contralateral breast
|
Interventional |
Phase 2 |
- Assaf-Harofeh Medical Center
- Rambam Health Care Campus
- Tel-Aviv Sourasky Medical Center
- (and 4 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Rate of contralateral breast cancer in carrier patients that received prophylactic radiation to the contralateral breast compared with carrier patients that did not receive that treatment.
- Short and long term adverse effects of prophylactic contralateral breast irradiation.
- factors that influence patient's choice of treatment
|
240 |
Female |
30 Years to 90 Years (Adult, Senior) |
NCT00496288 |
102/07 (HT4351) |
|
March 2008 |
March 2023 |
|
July 4, 2007 |
April 5, 2011 |
|
- Assaf-Harofeh Medical Center
Zerrifin, Israel
|
| 30 |
NCT02981485 |
Recruiting |
Fat Grafting Used for the Treatment of Breast Cancer Related Lymphedema in China |
|
|
Interventional |
Phase 2 |
- Peking Union Medical College
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in arm volume
- Change in tissue edema
- The function of the lymphatic vessel
- (and 2 more...)
|
30 |
Female |
20 Years to 60 Years (Adult) |
NCT02981485 |
CZ2015009 |
FGTBRCL |
December 2016 |
January 2018 |
January 2019 |
December 5, 2016 |
December 6, 2016 |
|
- Plastic Surgery Hospital of Chinese Academy of Medical Sciences, Peking Union Medical College
Shijingshan, Beijing, China
|
| 31 |
NCT03307044 |
Recruiting |
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies |
- Breast Carcinoma
- Cancer Survivor
- Cervical Carcinoma
- (and 2 more...)
|
- Procedure: Laser Therapy
- Other: Questionnaire Administration
|
Interventional |
Not Applicable |
- Ohio State University Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Ohio State University Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Vaginal Assessment Scale score
- Patient compliance rates
- Feasibility of laser treatments defined by completion rates and tolerability of treatment
- (and 2 more...)
|
40 |
Female |
Child, Adult, Senior |
NCT03307044 |
OSU-17153
NCI-2017-01554
P30CA016058 |
|
November 15, 2017 |
January 29, 2021 |
January 29, 2021 |
October 11, 2017 |
January 11, 2018 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
| 32 |
NCT02247037 |
Recruiting |
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer |
- Triple Negative Breast Cancer
|
|
Observational |
|
- Icahn School of Medicine at Mount Sinai
- Champions Oncology
|
Other / Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Patient Tumor Response
- Model Tumor Response
|
140 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02247037 |
GCO 14-0686 |
|
July 2014 |
June 2019 |
June 2019 |
September 23, 2014 |
July 21, 2017 |
|
- Mount Sinai Beth Israel
New York, New York, United States - Mount Sinai Roosevelt
New York, New York, United States - Mount Sinai St. Luke's
New York, New York, United States - Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai
New York, New York, United States
|
| 33 |
NCT02491957 |
Recruiting |
Impact of LOFT Therapy™ on Breast Cancer Survivors |
|
|
Interventional |
Not Applicable |
- Kathy Miller
- Indiana University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility of LOFT therapy in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy
- Safety of LOFT intervention in this population patient reported adverse events
- Heart rate
- (and 9 more...)
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02491957 |
IUSCC-0539 |
|
July 28, 2015 |
March 29, 2018 |
March 29, 2019 |
July 8, 2015 |
June 2, 2017 |
|
- Indiana University Health Hospital
Indianapolis, Indiana, United States - Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
|
| 34 |
NCT02493569 |
Not yet recruiting |
A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China |
|
- Procedure: The radical mastectomy of breast cancer
|
Observational |
|
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Observational Model: Ecologic or Community
- Time Perspective: Retrospective
|
- Overall five-year survival for the female breast cancer patients
|
3000 |
Female |
Child, Adult, Senior |
NCT02493569 |
KYLLSL-2015-153-01 |
|
October 2016 |
October 2017 |
|
July 9, 2015 |
August 10, 2016 |
|
|
| 35 |
NCT02464774 |
Not yet recruiting |
Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer |
|
- Procedure: Breast-Conserving Therapy
- Procedure: Mastectomy
- Drug: Adjuvant Chemotherapy
- Radiation: Radiation Therapy
|
Interventional |
Not Applicable |
- Xiaoming Xie
- Sun Yat-sen University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival(DFS)
- Locoregional recurrence-free survival(LRRFS)
- Distant metastasis (DM)
|
464 |
Female |
18 Years to 65 Years (Adult) |
NCT02464774 |
2014-FXY-093 |
|
July 2015 |
December 2022 |
|
June 8, 2015 |
June 8, 2015 |
|
|
| 36 |
NCT01901094 |
Recruiting |
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy |
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
|
- Procedure: Axillary Lymph Node Dissection (ALND)
- Radiation: Nodal Radiation Therapy
- Radiation: Axillary Radiation Therapy
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive breast cancer recurrence-free interval (IBC-RFI)
- Overall survival
- Ipsilateral/local/regional invasive breast cancer recurrence (ILR-REC)
|
2918 |
All |
18 Years and older (Adult, Senior) |
NCT01901094 |
A011202
U10CA031946
NCI-2013-00875 |
|
February 2014 |
January 2024 |
|
July 17, 2013 |
April 9, 2018 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1091 more...)
|
| 37 |
NCT02927912 |
Recruiting |
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction |
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
|
- Radiation: Electron Beam Therapy
- Procedure: Lumpectomy
- Other: Quality-of-Life Assessment
- (and 3 more...)
|
Interventional |
Phase 2 |
- Ohio State University Comprehensive Cancer Center
- Ohio State University Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events in the first 30 patients enrolled as graded by the National Cancer Institute Common Toxicity Criteria version 4.0
- Rate of grade 3 fibrosis using the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic scales
- Change in self-reported cosmesis using the BCTOS
- (and 3 more...)
|
176 |
Female |
18 Years to 59 Years (Adult) |
NCT02927912 |
OSU-16106
NCI-2016-01294 |
|
March 23, 2017 |
November 1, 2020 |
November 1, 2022 |
October 7, 2016 |
July 25, 2017 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
| 38 |
NCT02422498 |
Recruiting |
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy |
- Locally Recurrent/Metastatic Triple Negative Breast Cancer
|
- Radiation: external beam radiation therapy
- Drug: cisplatin
- Procedure: Biopsy of Target Tumor
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Cedars-Sinai Medical Center
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- response (RECIST 1.1 vs. PET Response Criteria (PRC) as measurement tools for treatment response)
|
54 |
Female |
18 Years and older (Adult, Senior) |
NCT02422498 |
15-032 |
|
April 2015 |
April 2019 |
April 2019 |
April 21, 2015 |
January 12, 2018 |
|
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - (and 3 more...)
|
| 39 |
NCT01992250 |
Recruiting |
Cryoablation of Small Breast Tumors in Early Stage Breast Cancer |
|
- Device: Visica 2 Treatment System
|
Interventional |
Not Applicable |
- Sanarus Technologies, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor ablation occurence
- Local tumor recurrence
- Satisfactory breast cosmesis results
- Adverse event assessment
|
200 |
Female |
50 Years and older (Adult, Senior) |
NCT01992250 |
CP-00-0011 |
FROST |
November 2013 |
December 2021 |
June 2023 |
November 25, 2013 |
April 20, 2018 |
|
- Arizona Breastnet
Scottsdale, Arizona, United States - 90210 Surgery Medical Center
Beverly Hills, California, United States - City of Hope
Duarte, California, United States - (and 9 more...)
|
| 40 |
NCT02052102 |
Recruiting |
Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart |
- Breast Cancer
- Adverse Effect of Radiation Therapy
|
- Radiation: Radiation therapy
|
Interventional |
Phase 2 |
- AHS Cancer Control Alberta
- Cross Cancer Institute
- AHS Cancer Control Alberta
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Radiation related acute and long term functional changes in patients treated with deep-inspiration breath hold compared to free-breathing technique
- Radiation dosimetric comparison
|
63 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT02052102 |
Breast-26159 |
|
October 2014 |
February 2017 |
March 2017 |
January 31, 2014 |
January 6, 2017 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada
|
| 41 |
NCT02186470 |
Recruiting |
Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer |
- Estrogen Receptor-positive Breast Cancer
- Invasive Ductal Breast Carcinoma
- Invasive Ductal Breast Carcinoma With Predominant Intraductal Component
- (and 7 more...)
|
- Radiation: accelerated partial breast irradiation
- Radiation: intensity-modulated radiation therapy
- Radiation: image-guided radiation therapy
- Procedure: therapeutic conventional surgery
|
Interventional |
Not Applicable |
- Ohio State University Comprehensive Cancer Center
- Ohio State University Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint will be the reproducibility of the MRI directed preoperative APBI treatment method
- Acute surgical and radiotherapy toxicity as scored by the National Cancer Institute Common Toxicity Criteria (NCI CTCAE) version 4.0
- Late surgical and radiotherapy toxicity as scored by the NCI CTCAE version 4.0
- (and 7 more...)
|
30 |
Female |
50 Years and older (Adult, Senior) |
NCT02186470 |
OSU-13282
NCI-2014-01248 |
|
June 2015 |
October 2018 |
October 2018 |
July 10, 2014 |
September 20, 2017 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
| 42 |
NCT02802098 |
Recruiting |
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer |
- Metastatic Breast Cancer
- Bevacizumab-alone Maintenance Treatment Progression
|
- Drug: Durvalumab
- Drug: Bevacizumab
|
Interventional |
Early Phase 1 |
- Centro Nacional de Investigaciones Oncologicas CARLOS III
- Fundación CRIS
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Changes Immunodynamics factors: kynurenine, prostaglandin, tryptophan levels
- T-cell exhaustion parameters
- T-cell exhaustion reversion
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
25 |
Female |
18 Years and older (Adult, Senior) |
NCT02802098 |
CNIO-BR-008
2015-005609-34 |
|
May 2016 |
May 2018 |
December 2018 |
June 16, 2016 |
September 14, 2017 |
|
- Hospital Universitario de Fuenlabrada
Fuenlabrada, Madrid, Spain - H. Arnau de Vilanova Lleida
Lleida, Spain - Hospital Universitario de la Princesa
Madrid, Spain - (and 4 more...)
|
| 43 |
NCT03077841 |
Recruiting |
Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer |
- Malignant Neoplasm of Breast
- Breast Cancer
|
- Radiation: External Radiation Therapy
- Behavioral: Questionnaires
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of grade 2 or Higher Treatment Toxicity with Optimizing Preventative Adjuvant Linac-Based Radiation (OPAL) Regimen
- Patient-Reported Cosmetic Outcome with Optimizing Preventative Adjuvant Linac-Based Radiation (OPAL) Regimen
|
150 |
Female |
50 Years and older (Adult, Senior) |
NCT03077841 |
2016-1035
NCI-2017-00476 |
|
March 6, 2017 |
March 2020 |
March 2021 |
March 13, 2017 |
March 12, 2018 |
|
- Community Health Network
Indianapolis, Indiana, United States - Cooper University Healthcare
Camden, New Jersey, United States - Ohio Health/Presbyterian MDA Radiation Treatment Center
Columbus, Ohio, United States - (and 7 more...)
|
| 44 |
NCT02828189 |
Recruiting |
Therapeutic Exercise in Cancer-Related Fatigue in Women After Breast Cancer Treatment |
|
- Other: Physical Exercise
- Behavioral: Therapeutic Education
- Other: Therapeutic exercise-Physiotherapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- "6-Minutes Walking Test (6MWT)"
- Karnofsky Performance Status.
- Quality of life
- (and 3 more...)
|
90 |
Female |
18 Years to 85 Years (Adult, Senior) |
NCT02828189 |
FPSM_UAH_VPG_2 |
|
May 2015 |
October 2016 |
February 2017 |
July 11, 2016 |
July 11, 2016 |
|
- Teacher care and research in physiotherapy Unit. Department of Physiotherapy. University of Alcala.
Alcalá de Henares, Madrid, Spain
|
| 45 |
NCT02769104 |
Recruiting |
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer |
|
- Drug: Letrozole (Aromatase Inhibitors)
- Drug: AC*4-T*4
|
Interventional |
Phase 3 |
- Zhejiang Cancer Hospital
- Zhejiang Cancer Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- effective rate
- pCR
- disease-free survival (DFS)
- side effect rate
|
120 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT02769104 |
ZJCH-ACCN |
ACCN |
May 2016 |
July 2018 |
December 2019 |
May 11, 2016 |
January 9, 2018 |
|
- Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
|
| 46 |
NCT03140553 |
Recruiting |
TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer |
- HER2-Positive Breast Cancer
|
- Drug: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
|
Interventional |
Phase 2 |
- Guangdong General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
70 |
Female |
18 Years and older (Adult, Senior) |
NCT03140553 |
20170308 |
|
September 1, 2016 |
September 1, 2018 |
September 1, 2019 |
May 4, 2017 |
May 4, 2017 |
|
- Guangdong General Hospital
Guangzhou, Guangdong, China
|
| 47 |
NCT02798484 |
Recruiting |
Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging |
|
- Device: Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)
|
Interventional |
Not Applicable |
- Brugmann University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Apparent diffusion coefficient (ADC) (mm2/sec)
- Anatomo-pathology classification - histological type
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT02798484 |
CHUB-CNA |
|
June 2016 |
June 2017 |
June 2017 |
June 14, 2016 |
July 26, 2016 |
|
- CHU Brugmann
Brussels, Belgium
|
| 48 |
NCT02958852 |
Recruiting |
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer |
|
- Drug: Letrozole
- Drug: Letrozole and atorvastatin
- Drug: Fulvestrant
|
Interventional |
Phase 2 |
- Lund University Hospital
- South Sweden Breast Cancer Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical benefit rate.
- Progression free survival.
- Objective response rate.
- (and 4 more...)
|
126 |
Female |
18 Years and older (Adult, Senior) |
NCT02958852 |
OKFE 15-ABC-SE |
ABC-SE |
November 2016 |
April 2022 |
April 2022 |
November 8, 2016 |
March 12, 2018 |
|
- Lund University Hospital, Department of Oncology
Lund, Sweden
|
| 49 |
NCT03355157 |
Not yet recruiting |
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting. |
|
- Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
|
Interventional |
Phase 4 |
- German Breast Group
- Pfizer
- Advanced Medical Services
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time-to-treatment failure (TTF)
|
360 |
All |
18 Years and older (Adult, Senior) |
NCT03355157 |
GBG 93
2016-004482-89 |
PADMA |
December 1, 2017 |
December 31, 2021 |
December 31, 2021 |
November 28, 2017 |
November 28, 2017 |
|
|
| 50 |
NCT03227328 |
Recruiting |
CHemo-ENDOcrine Therapy in Advanced Breast Cancer |
- Breast Cancer
- Metastatic Breast Cancer
- Luminal B
|
- Drug: concomitant chemotherapy plus an aromatase inhibitor (AI)
- Drug: chemotherapy followed by an aromatase inhibitor (AI)
|
Interventional |
Phase 3 |
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- Agenzia Italiana del Farmaco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- EORTC QLQ-C30 quality of life between the 2 arms
- QLQ-BR23 quality of life between the 2 arms
- (and 8 more...)
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT03227328 |
IRST174.19
2016-004107-31 |
CHENDO |
August 2, 2017 |
July 2019 |
September 2020 |
July 24, 2017 |
August 21, 2017 |
|
- U.O. Oncologia Medica, P.O. Bellaria-Maggiore
Bologna, BO, Italy - UO Oncologia Medica IRST IRCCS
Meldola, FC, Italy - Dip. Medicina Interna e Riabilitazione - U.O. Medicina Interna Oncologica, Ospedale Ramazzini
Carpi, MO, Italy - (and 8 more...)
|
Create an RSS feed from your search for:
Download the search results for: